Xenon Pharmaceuticals
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. They focus on human channelopathies and have strong capabilities in small molecule ion channel drug discovery, leveraging genetics, proprietary biology, and medicinal chemistry assets.
Industries
Nr. of Employees
medium (51-250)
Xenon Pharmaceuticals
3650 Gilmore Way, Burnaby, BC V5G 4W8
Patents
Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
US-11639351-B2
View Details
Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
US-11639351-B2
View DetailsProducts
Lead Kv7 potassium channel opener clinical candidate (oral capsule)
A once-daily oral small-molecule Kv7 channel opener being evaluated in Phase 3 clinical trials for focal-onset seizures and primary generalized tonic-clonic seizures and in clinical studies for major depressive disorder.
Partnered sodium-channel inhibitor development program
Collaborative development of selective and dual voltage-gated sodium channel inhibitors (targeting NaV isoforms) for genetic and other epilepsy indications.
Lead Kv7 potassium channel opener clinical candidate (oral capsule)
A once-daily oral small-molecule Kv7 channel opener being evaluated in Phase 3 clinical trials for focal-onset seizures and primary generalized tonic-clonic seizures and in clinical studies for major depressive disorder.
Partnered sodium-channel inhibitor development program
Collaborative development of selective and dual voltage-gated sodium channel inhibitors (targeting NaV isoforms) for genetic and other epilepsy indications.
Services
Protocol design, site selection, project management, CRO/vendor coordination, clinical operations and open-label extension management for multicenter trials.
CRF and EDC design, database validation and maintenance, CDISC/SDTM dataset generation and SAS-based data analysis.
In vivo efficacy and disease-model pharmacology, electrophysiology and qECoG assessments to support candidate selection and mechanism-of-action evaluation.
Design, synthesis, purification and characterization of small-molecule candidates with integration of DMPK, metabolism and physicochemical profiling.
Establishing selective partnerships with pharmaceutical companies for access to development/commercial resources and collaborative programs.
Protocol design, site selection, project management, CRO/vendor coordination, clinical operations and open-label extension management for multicenter trials.
CRF and EDC design, database validation and maintenance, CDISC/SDTM dataset generation and SAS-based data analysis.
In vivo efficacy and disease-model pharmacology, electrophysiology and qECoG assessments to support candidate selection and mechanism-of-action evaluation.
Design, synthesis, purification and characterization of small-molecule candidates with integration of DMPK, metabolism and physicochemical profiling.
Establishing selective partnerships with pharmaceutical companies for access to development/commercial resources and collaborative programs.
Expertise Areas
- Clinical trial management (Phases 1–3)
- Clinical data management and CDISC/SDTM implementation
- Ion channel-focused small-molecule discovery
- Medicinal chemistry and SAR-driven lead optimization
Key Technologies
- Kv7 potassium channel modulation
- Voltage-gated sodium channel modulation (Nav1.6, Nav1.2, Nav1.1)
- Rodent seizure models and disease-model pharmacology (e.g., Dravet mouse)
- Quantitative electrocorticography (qECoG) and electrophysiology assays